{
    "Trade/Device Name(s)": [
        "Yumizen C1200 CRP"
    ],
    "Submitter Information": "HORIBA ABX SAS",
    "510(k) Number": "K192028",
    "Predicate Device Reference 510(k) Number(s)": [
        "K142993"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DCK"
    ],
    "Summary Letter Date": "June 25, 2020",
    "Summary Letter Received Date": "July 26, 2019",
    "Submission Date": "July 25, 2019",
    "Regulation Number(s)": [
        "21 CFR 866.5270"
    ],
    "Regulation Name(s)": [
        "C-reactive protein immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "C-reactive protein"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Lithium heparin plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Yumizen C1200 Clinical Chemistry Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoturbidimetry",
        "Latex-enhanced immunoturbidimetric assay"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Yumizen C1200 CRP reagent for quantitative determination of C-reactive protein in serum and lithium heparin plasma on the Yumizen C1200 analyzer using immunoturbidimetric technology",
    "Indications for Use Summary": "Quantitative in vitro diagnostic determination of C-reactive protein in human serum and lithium heparin plasma to aid evaluation of injury, infection, or inflammatory disorders, used alongside other laboratory and clinical findings",
    "fda_folder": "Immunology"
}